Check-Cap Ltd. - Asset Resilience Ratio
Check-Cap Ltd. (MBAI) has an Asset Resilience Ratio of 2.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Check-Cap Ltd.'s Asset Resilience Ratio has changed over time. Check Check-Cap Ltd. (MBAI) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Check-Cap Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MBAI market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $217.00K | 2.9% |
| Total Liquid Assets | $217.00K | 2.90% |
Asset Resilience Insights
- Limited Liquidity: Check-Cap Ltd. maintains only 2.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Check-Cap Ltd. Industry Peers by Asset Resilience Ratio
Compare Check-Cap Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Clinica Baviera
MC:CBAV |
Diagnostics & Research | 14.23% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 18.64% |
|
Predilife
PA:ALPRE |
Diagnostics & Research | 16.23% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Check-Cap Ltd. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Check-Cap Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.90% | $217.00K | $7.49 Million | -60.71pp |
| 2023-12-31 | 63.60% | $15.91 Million | $25.02 Million | -19.16pp |
| 2022-12-31 | 82.76% | $37.61 Million | $45.44 Million | +37.66pp |
| 2021-12-31 | 45.10% | $25.10 Million | $55.66 Million | -- |
About Check-Cap Ltd.
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.